Romano Brothers & Co’s Takeda Pharmaceutical TAK Stock Holding History

Romano Brothers & Co’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-140	Closed	-$2.18K	–	898
2022 Q4	$2.18K	Buy	+140	New	+$1.96K	﹤0.01%	929

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Romano Brothers & Co's TAK Position: Q1 2023 in Review

Romano Brothers & Co sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 140 shares — an estimated $2.18K sold.

Romano Brothers & Co first reported a position in TAK in Q4 2022 and held it in 1 quarter. The position peaked at $2.18K in Q4 2022. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

Romano Brothers & Co reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 140 Takeda Pharmaceutical shares in Q1 2023, an estimated $2.18K.
Romano Brothers & Co first reported a position in Takeda Pharmaceutical in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's Takeda Pharmaceutical position peaked at $2.18K in Q4 2022.
300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.